Lead Product(s) : Namodenoson
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Can-Fite's Namodenoson Shows Liver Cirrhosis Episode Disappearance
Details : CF102 (namodenoson) is a small orally bioavailable drug that binds to the A3AR. It is being evaluated for the treatment of Decompensated Liver Cirrhosis.
Product Name : CF102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Namodenoson
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Namodenoson
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
Details : CF102 (namodenoson) is a small orally bioavailable drug that binds to the A3AR. It is being evaluated for the treatment of Decompensated Liver Cirrhosis.
Product Name : CF102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2024
Lead Product(s) : Namodenoson
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aramchol meglumine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aramchol meglumine is a first-in-class, novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, liver targeted SCD1 modulato which is being developed for the treatment of primary sclerosing cholangitis.
Product Name : Aramchol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2023
Lead Product(s) : Aramchol meglumine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX003
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Presentation featured at The Liver Meeting® 2020, the AASLD Annual Meeting, details support for the design of phage therapy candidate BX003, an orally delivered candidate phage therapy targeting Klebsiella pneumoniae for the treatment of both IBD and PS...
Product Name : BX003
Product Type : Microorganism
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : BX003
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable